NASDAQ:ADPT Adaptive Biotechnologies (ADPT) Stock Forecast, Price & News $7.30 +0.25 (+3.55%) (As of 10:40 AM ET) Add Compare Share Share Today's Range$7.12▼$7.3150-Day Range$6.19▼$8.8352-Week Range$5.95▼$13.21Volume298,494 shsAverage Volume940,265 shsMarket Capitalization$1.05 billionP/E RatioN/ADividend YieldN/APrice Target$13.80 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Adaptive Biotechnologies MarketRank™ ForecastAnalyst RatingHold2.25 Rating ScoreUpside/Downside90.6% Upside$13.80 Price TargetShort InterestBearish4.76% of Float Sold ShortDividend StrengthN/ASustainability-0.79Upright™ Environmental ScoreNews Sentiment0.62Based on 7 Articles This WeekInsider TradingSelling Shares$354,339 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.20) to ($0.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.30 out of 5 starsMedical Sector795th out of 1,980 stocksBiological Products, Except Diagnostic Industry103rd out of 330 stocks 3.1 Analyst's Opinion Consensus RatingAdaptive Biotechnologies has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.80, Adaptive Biotechnologies has a forecasted upside of 90.6% from its current price of $7.24.Amount of Analyst CoverageAdaptive Biotechnologies has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.76% of the float of Adaptive Biotechnologies has been sold short.Short Interest Ratio / Days to CoverAdaptive Biotechnologies has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Adaptive Biotechnologies has recently increased by 8.87%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdaptive Biotechnologies does not currently pay a dividend.Dividend GrowthAdaptive Biotechnologies does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAdaptive Biotechnologies has received a 61.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Basic medical research services", "Scientific databases", and "Medical laboratory automation systems" products. See details.Environmental SustainabilityThe Environmental Impact score for Adaptive Biotechnologies is -0.79. Previous Next 3.7 News and Social Media Coverage News SentimentAdaptive Biotechnologies has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Adaptive Biotechnologies this week, compared to 5 articles on an average week.Search Interest15 people have searched for ADPT on MarketBeat in the last 30 days. This is an increase of 275% compared to the previous 30 days.MarketBeat Follows7 people have added Adaptive Biotechnologies to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adaptive Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $354,339.00 in company stock.Percentage Held by InsidersOnly 4.20% of the stock of Adaptive Biotechnologies is held by insiders.Percentage Held by Institutions90.75% of the stock of Adaptive Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Adaptive Biotechnologies are expected to grow in the coming year, from ($1.20) to ($0.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptive Biotechnologies is -5.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptive Biotechnologies is -5.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptive Biotechnologies has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Adaptive Biotechnologies (NASDAQ:ADPT) StockAdaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.Read More Receive ADPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address ADPT Stock News HeadlinesJune 2, 2023 | finance.yahoo.comAdaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic CancerMay 31, 2023 | americanbankingnews.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Short Interest Up 8.9% in MayJune 2, 2023 | Edge On The Street (Ad)Is Graphite the New Lithium?Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.May 29, 2023 | finance.yahoo.comStrong week for Adaptive Biotechnologies (NASDAQ:ADPT) shareholders doesn't alleviate pain of three-year lossMay 26, 2023 | msn.comDetails Released For Adaptive Programs Coming To OrangeMay 22, 2023 | msn.comUAH hosts Adaptive Cycling Community Day and ClinicMay 19, 2023 | msn.comUnusual Call Option Trade in Adaptive Biotechnologies (ADPT) Worth $27.50KMay 14, 2023 | americanbankingnews.comShort Interest in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Grows By 12.2%June 2, 2023 | Edge On The Street (Ad)The Graphite Shortage Story You're Not Being ToldGraphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security. May 12, 2023 | msn.comAdaptive Biotechnologies's Return On Capital Employed InsightsMay 12, 2023 | finance.yahoo.comAdaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare ConferenceMay 10, 2023 | americanbankingnews.comAdaptive Biotechnologies (NASDAQ:ADPT) PT Raised to $15.00 at Piper SandlerMay 9, 2023 | finance.yahoo.comAdaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in OncologyMay 9, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Adaptive Biotechnologies Co. (NASDAQ:ADPT) Boosted by William BlairMay 6, 2023 | msn.comMorgan Stanley Maintains Adaptive Biotechnologies (ADPT) Equal-Weight RecommendationMay 6, 2023 | americanbankingnews.comAdaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Down After Earnings MissMay 4, 2023 | finance.yahoo.comQ1 2023 Adaptive Biotechnologies Corp Earnings CallMay 3, 2023 | seekingalpha.comAdaptive Biotechnologies Corporation (ADPT) Q1 2023 Earnings Call TranscriptMay 3, 2023 | msn.comAdaptive Biotechnologies: Q1 Earnings InsightsMay 3, 2023 | finance.yahoo.comAdaptive Biotechnologies Reports First Quarter 2023 Financial ResultsMay 3, 2023 | markets.businessinsider.comAdaptive Biotechnologies Q1 Loss decreases, but misses estimatesMay 2, 2023 | markets.businessinsider.comHere's what Wall Street expects from Adaptive Biotechnologies's earningsMay 2, 2023 | americanbankingnews.comShort Interest in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Decreases By 11.3%May 1, 2023 | americanbankingnews.comAdaptive Biotechnologies (ADPT) Set to Announce Quarterly Earnings on WednesdayApril 28, 2023 | marketwatch.comAdaptive Security Architecture (ASA) Market Top Manufacturers By 2030April 27, 2023 | marketwatch.comAdaptive Learning Software Market Trends [2023-2030] Tracking the Latest Market DevelopmentsApril 26, 2023 | marketwatch.com2023 Adaptive Hair Dryer Market Size and New Developments with [106 Pages] | Exclusive Report till 2030See More Headlines ADPT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADPT Company Calendar Last Earnings5/03/2023Today6/02/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADPT CUSIPN/A CIK1478320 Webwww.constructionpartners.net Phone(206) 659-0067Fax206-659-0667Employees858Year Founded2009Price Target and Rating Average Stock Price Forecast$13.80 High Stock Price Forecast$17.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+95.7%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-200,190,000.00 Net Margins-105.87% Pretax Margin-105.93% Return on Equity-41.21% Return on Assets-23.38% Debt Debt-to-Equity RatioN/A Current Ratio5.56 Quick Ratio5.34 Sales & Book Value Annual Sales$185.31 million Price / Sales5.49 Cash FlowN/A Price / Cash FlowN/A Book Value$2.94 per share Price / Book2.40Miscellaneous Outstanding Shares144,310,000Free Float138,250,000Market Cap$1.02 billion OptionableNot Optionable Beta1.18 Social Links Key ExecutivesChad RobinsChairman & Chief Executive OfficerJulie RubinsteinPresident & Chief Operating OfficerTycho W. PetersonChief Financial OfficerHarlan RobinsChief Scientific OfficerZhou YiChief Technical OfficerKey CompetitorsInhibrxNASDAQ:INBXReplimune GroupNASDAQ:REPLImmunityBioNASDAQ:IBRXSana BiotechnologyNASDAQ:SANAExscientiaNASDAQ:EXAIView All CompetitorsInsiders & InstitutionsMacquarie Group Ltd.Bought 29,655 shares on 6/1/2023Ownership: 0.061%Prelude Capital Management LLCBought 12,776 shares on 6/1/2023Ownership: 0.025%ProShare Advisors LLCSold 3,123 shares on 5/26/2023Ownership: 0.016%Legato Capital Management LLCBought 71,683 shares on 5/25/2023Ownership: 0.050%Putnam Investments LLCSold 8,520 shares on 5/22/2023Ownership: 0.140%View All Insider TransactionsView All Institutional Transactions ADPT Stock - Frequently Asked Questions Should I buy or sell Adaptive Biotechnologies stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADPT, but not buy additional shares or sell existing shares. View ADPT analyst ratings or view top-rated stocks. What is Adaptive Biotechnologies' stock price forecast for 2023? 4 Wall Street research analysts have issued twelve-month price targets for Adaptive Biotechnologies' shares. Their ADPT share price forecasts range from $7.00 to $17.00. On average, they anticipate the company's stock price to reach $13.80 in the next year. This suggests a possible upside of 95.7% from the stock's current price. View analysts price targets for ADPT or view top-rated stocks among Wall Street analysts. How have ADPT shares performed in 2023? Adaptive Biotechnologies' stock was trading at $7.64 on January 1st, 2023. Since then, ADPT stock has decreased by 7.7% and is now trading at $7.05. View the best growth stocks for 2023 here. Are investors shorting Adaptive Biotechnologies? Adaptive Biotechnologies saw a increase in short interest in May. As of May 15th, there was short interest totaling 6,630,000 shares, an increase of 8.9% from the April 30th total of 6,090,000 shares. Based on an average daily volume of 856,600 shares, the short-interest ratio is presently 7.7 days. Currently, 4.8% of the shares of the stock are sold short. View Adaptive Biotechnologies' Short Interest. When is Adaptive Biotechnologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our ADPT earnings forecast. How were Adaptive Biotechnologies' earnings last quarter? Adaptive Biotechnologies Co. (NASDAQ:ADPT) released its earnings results on Wednesday, May, 3rd. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.06. The firm earned $37.65 million during the quarter, compared to analysts' expectations of $36.81 million. Adaptive Biotechnologies had a negative trailing twelve-month return on equity of 41.21% and a negative net margin of 105.87%. The business's quarterly revenue was down 2.5% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.44) EPS. What ETFs hold Adaptive Biotechnologies' stock? ETFs with the largest weight of Adaptive Biotechnologies (NASDAQ:ADPT) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), ETFMG Treatments Testing and Advancements ETF (GERM), Invesco Nasdaq Future Gen 200 ETF (QQQS), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Principal Healthcare Innovators ETF (BTEC), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ) and ProShares Ultra Nasdaq Biotechnology (BIB). What guidance has Adaptive Biotechnologies issued on next quarter's earnings? Adaptive Biotechnologies issued an update on its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $205.00 million-$215.00 million, compared to the consensus revenue estimate of $208.52 million. What is Chad Robins' approval rating as Adaptive Biotechnologies' CEO? 51 employees have rated Adaptive Biotechnologies Chief Executive Officer Chad Robins on Glassdoor.com. Chad Robins has an approval rating of 92% among the company's employees. This puts Chad Robins in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Adaptive Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptive Biotechnologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), QUALCOMM (QCOM), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Home Depot (HD), Inovio Pharmaceuticals (INO), PayPal (PYPL) and Tesla (TSLA). When did Adaptive Biotechnologies IPO? (ADPT) raised $200 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 12,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers. What is Adaptive Biotechnologies' stock symbol? Adaptive Biotechnologies trades on the NASDAQ under the ticker symbol "ADPT." Who are Adaptive Biotechnologies' major shareholders? Adaptive Biotechnologies' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.15%), ARK Investment Management LLC (6.43%), Sumitomo Mitsui Trust Holdings Inc. (3.72%), Nikko Asset Management Americas Inc. (3.72%), State Street Corp (1.78%) and Geode Capital Management LLC (1.54%). Insiders that own company stock include Chad M Cohen, Chad M Cohen, Chad M Robins, Chad M Robins, Charles Sang, David E Goel, Egon Durban, Eric Dobmeier, Euclidean Capital Llc, Francis Lo, Global Investors Lp Viking, Harlan S Robins, Harlan S Robins, Julie Rubinstein, Jyoti Palaniappan, Kyle Piskel, Lance Baldo, Michael J Pellini, Michelle Renee Griffin, Nancy Louise Hill, Nitin Sood, R Mark Adams, Robert Hershberg, Sharon Benzeno, Stacy L Taylor and Susan Bobulsky. View institutional ownership trends. How do I buy shares of Adaptive Biotechnologies? Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Adaptive Biotechnologies' stock price today? One share of ADPT stock can currently be purchased for approximately $7.05. How much money does Adaptive Biotechnologies make? Adaptive Biotechnologies (NASDAQ:ADPT) has a market capitalization of $1.02 billion and generates $185.31 million in revenue each year. The company earns $-200,190,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. How many employees does Adaptive Biotechnologies have? The company employs 858 workers across the globe. How can I contact Adaptive Biotechnologies? Adaptive Biotechnologies' mailing address is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. The official website for the company is www.constructionpartners.net. The company can be reached via phone at (206) 659-0067, via email at investors@adaptivebiotech.com, or via fax at 206-659-0667. This page (NASDAQ:ADPT) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.